Sun Pharmaceutical Industries

1983
 
 - The Company was incorporated as a partnership firm by Dilip Sanghvi
 &
 his family to manufacture pharmaceutical formulation at Vapi,
 Gujarat.
 It was converted into a public Ltd. Company effective 1st March. 
 The
 was promoted by Dilip Sanghvi.  The Company specialises in selected
 therapeutic segment to psychiatry, cardiology, neurology and
 gastroenterology.
 
 1994
 
 - The Bulk drug plant at Panoli was commissioned.  The second
 formulation plant at Silvana was commissioned in April.
 
 - During October, the company undertook to enhance the production
 capacity of bulk drugs at Panoli from 62,000 Kgs. p.a. to 92000 Kgs.
 p.a.  Also formulation unit was to be enhanced to 1800 millions
 tablets
 p.a. from 570 million tablets p.a.
 
 - The Company proposed to modernise the formulation unit at Vapi and
 increase its capacity from 480 million tablets to 1440 million
 tablets
 p.a.  It was also proposed to set up additional facilities at the
 R&D
 centre SPARC.
 
 - 71,85,000 No. of equity shares issued to promoters etc.
 
 1995
 
 - In the synergy division two more products viz. `Clofranil SR and
 Syndopa CR were introduced.
 
 - The Company entered into a MOU with Knoll Pharmaceuticals Ltd. 
 for
 acquisition of their Ahmednagar unit manufacturing bulk drugs.
 
 - 35,92,500 No. of equity shares allotted as bonus shares in prop.
 1:2.  3,23,400 Rights shares issued at a premium of Rs 130 per
 shares.
 During October 1994, the capital issued 37,00,300 No. of equity
 shares
 of Rs 10 each at a premium of Rs 140 per share to the public.
 
 1996
 
 - 18 new products were launched across the company's six focused
 marketing divisions and 4 more line extension including drug
 delivery
 systems were launched.
 
 - The Company acquired controlling stake in MJ Pharmaceuticals Ltd.
 
 - SPIL and its group company Virtuous Finance Ltd., which are the
 the
 major shareholders of MJPL with more than 50 per cent of
 shareholding,
 had signed a MoU with erstwhile promoters the Shah family, on
 November
 1.
 
 1997
 
 
 - The Company acquired 78,36,000 No. of equity shares of Rs 10 each.
 
 - The Chennai based Tamil Nadu Dadha Pharmaceuticals Co. Ltd.  was
 merged with the company in the ratio of 4:1 effective 1st April. 
 With
 this, IDPL brings to sun pharma extensive product strengths across
 the
 areas of gynaecology, fertility, oncology, pain mengeners and
 duaesthelics.
 
 - Sunkalp Laboratories Ltd., Sun Pharma Industries Ltd., Russia &
 Sun
 Pharma Global Inc. are all subsidiaries of the Company.
 
 - 4,13,633 No. of equity shares allotted to erstwhile shareholders
 of
 Tamil Nadu, Dadha Pharmaceuticals pursuant to a scheme of
 amalgamation.
 
 - The boards of Tamilnadu Dadha Pharmaceuticals Ltd. (TDPL) and Sun
 Pharmaceuticals Ltd. have approved a 1:4 swap ratio for the merger
 of
 the companies.
 
 - The company also set up a state of the art research centre named
 Sun
 Pharma advanced Research Centre (SPARC) in Vadodara.
 
 - Sun Pharmaceuticals to set a new tablet manufacturing facility at
 Silvassa in Dadra and Nagar Haveli as part of its strategy to
 maximize
 benefits on the tax shelter front.  The new unit is expected to come
 up
 close to Sun's existing formulations facility at piparia in
 Silvassa.
 
 1998
 
 - During the year the company launched Duracard that not only
 affects
 Blood pressure but also has beneficial effect on the cholestrol
 profile
 and glucose metabolishm.
 
 - Another product launched was Cardivas, that has an ability to pump
 blood through the body there by reducing the strain on the heart
 during
 heart failure.
 
 - The company also launched Muvera, an anti inflammatory drug and
 Octapeptide Octride, an emergency medication in treating oesophagel
 varices, severe bleeding in the upper part of the gastrointestinal
 tract and also in the treatment of acromegaly an endocrine disorder
 caused by the excess growth of hormone secretion.
 
 - 2,08,000 shares of Rs. 10 each allotted to shareholders of
 erstwhile
 Milment Labs. Pvt. Ltd. Pursuant to a scheme of amalgamation.
 
 - Sun Pharmaceuticals Industries has converted its partnership
 export
 entity, Sun Pharma Exports, into a 100 per cent subsidiary,
 effective
 from 5th May.
 
 - Sun Pharma Exports, a partnership firm in which SPIL held 80 per
 cent
 stake, to Sunkalp Laboratories, a 100 per cent subsidiary of SPIL,
 with
 effect from 12th May.
 
 - In addition to this the company has set up state-of-the-art
 facilities for R&D in Baroda to carry out research in
 pharmaceuticals.
 
 1999
 
 
 - A leading Indian Company will set up a pharmaceutical plant in
 Bangladesh under a joint venture.
 
 - The hiving-off of Sun Pharmaceutical Exports into a 100 per cent
 subsidiary and increase in interest burden affected the bottomline.
 
 2000
 
 - The Company has merged its wholly owned export subsidiary Sun
 Pharma
 Exports with itself.
 
 - The Company is looking at an over 70 per cent growth rate in
 India,
 driven primarily by the company's products and education services
 segment.
 
 - As per the Scheme of Amalgamation, SPIL shall issue four equity
 shares of Rs 10 each of SPIL to the members of SPEL for every five
 equity shares held in SPEL.
 
 - The Company, on 1st April, allotted 3,08,44,466 Bonus Equity
 Shares
 of Rs. 10/- each, to the shaeholders of hte Company in the ratio o f
 2
 Bonus Equity shares for eveyr 1 Equity share held by the
 shareholders
 and Bonus equity Shares will be entitled to any dividend declared
 after
 1st April.
 
 - The Company has launched Edegra (Sidenefil) in 25, 50 and 100mg.
 
 - During June 2000, the company introduced several products
 including
 Celact (celecoxib), Oleanz (olanzapine), Rofact (rofecoxib), Nodict
 (naltrexone), Fexotrol (fexofenadine), Zelast (azolastine) and
 (Ketorid(ketotifen).
 
 - In June 2000, Sun Pharma merged its 99.28% subsidiary - Sun
 Pharmaceuticals Exports.
 
 2001
 
 - Sun Pharmaceutical Industries Ltd has approved the merger of the
 ailing Pradeep Drug Company Ltd.
 
 - Sun Pharmaceutical Industries Ltd. is to merge its research arm
 Sun
 Pharmaceutical Advanced Research Centre Ltd.
 
 - During 2000-01, across the company's eight speciality divisions,
 33
 new products were launched. Taking the lead for new products among
 the
 therapy areas were cardiology (6 products), diabetology (4) and
 opthalmology (6). Likely brand outperformers among these are the
 antihypertensive Irovel (Rapilin, Pioglit, Rezult) for antidiabetics
 and the erectile dysfunction treatment Edegra.
 
 - The company, ranked 5th by domestic prescription product sales,
 has
 been consistently adding to market share from 2.47% in November 2000
 to
 2.78% in November 2001 (ORG Retail Chemist Audit, November 2000 and
 2001). Forbes Global, the prestigious international magazine
 recently
 rated Sun Pharma among the best 200 global companies for 2002
 (turnover
 less than 0mill).
 
 2002
 
 -Caraco Pharmaceutical Laboratories, associate of Sun
 Pharmaceuticals, has received US Food and Drug Authority (FDA)
 preliminary approval for metformin hydrochloride, a molecule used to
 treat diabetes.
 
 - Currently, the company is in process of merging Pradeep Drug
 Company
 (PDC) with itself. The company shareholders have approved the merger
 w.e.f. 1 April 2000. The scheme has been duly sanctioned by BIFR at
 its
 meeting held on Jan 2002.
            
 - Sun Pharma has made an open offer to the investors in Ahmedabad,
 Calcutta, Madras, Pondicherry and Delhi stock exchages to purchase
 the shares at price of Rs 600 per share. The offer is limited to
 those shareholders whose names are registered as members of the
 company as on 26/03/2002, the record date. 
 
 -Sun Pharmaceutical Industries has launched Lupride Depot IM, a novel
 drug delivery system of prostate cancer drug leuprolide acetate, which
 would enabel the drug to be injected once in a month as against once
 in a day or once in three days drugs.
 
 -Mr Keki Mistry, Managing Director of HDFC, has been inducted into
 the board of directors of Sun Pharmaceuticals Industries Ltd.
 
 -The Board of Directors of Sun Pharmaceutical Industries Ltd at its
 meeting held allotted 18,71,77,232 6% Cumulative Redeemable
 Preference Shares of Re 1 each as Bonus Shares in the ratio of 4:1
 (ie 4 Preference Shares of Re 1 each for every one equity shares of
 Rs 10 each) to the equity shareholders of the company as on the
 record date October 10, 2002.
 
 2003
 
 -Sun Pharmaceutical Industries Ltd (Sun Pharma) has announced the
 Buyback of fully paid-up equity shares of the Company of face value
 of Rs 10 each and / or Rs 5 each (being face value and paid up value
 subsequent to the splitting of the equity shares of Rs 10 into 2
 equity shares) not exceeding 2,000,000 equity shares of Rs 10 each
 and/or 4,000,000 equity shares of Rs 5 each i.e. not exceeding equity
 shares of face value of Rs 20,000,000 being less than 25% of the
 paid-up equity share capital of the company for an aggregate amount
 not exceeding Rs 1200,000,000 upto a maximum price of Rs 750 per
 equity share of Rs 10 each or upto a maximum price of Rs 375 per
 equity share of Rs 5 each from the existing shareholders and
 beneficial owners of the shares of the company from open market
 through stock exchanges. 
 
 -Sun Pharmaceuticals Industries Ltd has informed the Exchange that
 the Board of Directors at its meeting held on January 30, 2003
 accepted the resignation of Shri R K Baheti, Senior Vice President -
 Finance and Company secretary of the Company w.e.f 31/1/2003 and the
 Board appointed Shri Kamlesh H Shah as the Company Secretary w.e.f.
 31/1/2003.
 
 -Sun Pharmaceuticals’ US-based associate, Caraco Pharmaceutical
 Laboratories, has received the approval from the US Food and Drug
 Administration (US FDA) to manufacture and market yet another generic
 drug, this time for the treatment of mild to moderate cardiac failure,
 in the US. The drug, Digoxin, is the generic form of Glaxo Wellcome’s
 Lanoxin, the company said.
 
 -Sun Pharmaceutical Industries Ltd has informed BSE that it has
 further redeemed 1,42,99,833, 6% Cumulative Redeemable Preference
 Shares of Re 1 each amounting to Rs 1,42,99,833 in the fifth lot out
 of the total paid - up Preference Share Capital of the company.
 
 -Sun Pharmaceuticals Industries Ltd has informed the Exchange that
 the company pursuant to the earlier intimation about Redemption of
 Preference Shares, have extinguished /cancelled 3,01,20,608 shares -
 6% Cumulative Redeemable Preference Shares of Re.1/- each consisting
 of 2,98,37,008 Preference Shares in demat mode and 2,93,376
 Preference Shares in physical mode.
 
 -Board approved to close buy back of shares
 
 -The company's equity shares will be delisted from Vadodara Stock
 Exchange Ltd.
 
 2004
 
 -Sun Pharmaceutical Industries purchases additional stake in Caraco
 enhacing its holding to 63.14%
 
 2007
 
 - Sun Pharmaceutical acquires Taro for 4 mn